VLRX
Valeritas Holdings, Inc.

Market cap $22.024M
Enterprise value $23.04M
Employees 82
Revenue $19.3M
EBITDA -$35.8M
Income -$45.4M
EPS -10.42
P/E N/A
Forward P/E -0.49
EV/EBITDA -0.64
PEG N/A
Earnings date 2017-08-08
Volume 908 / 44.7k
Relative vol. 0.02 ×
Profit margin -229.55%
Oper. margin -197.33%
Gross margin 36.05%
Ret. on assets -47.88%
Return on equity -67,922.22%
Sales Q/Q 5.61%
Sales Y/Y 246,776.16%
Est. EPS Q/Q N/A
Beta N/A
Mean Recomm. 2.00
IPO year 2017
Country United States
RSI 34.95
Range $3.05 – $3.14
52 weeks $2.00 – $27.60
SMA 50 $3 +7.47%
SMA 200 $3 +10.40%
1 year target $12 +292.16%

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

10 years

All time

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-08-21 Peter Devlin
Director
Director Buy 3,000 $3.81 $11,430
2017-08-21
3,000
2017-08-18 John Edward Timberlake
See Remarks
See Remarks Buy 3,500 $3.70 $12,950
2017-08-18
33,537
2017-08-18 Joseph M Mandato
Director
Director Buy 912 $3.68 $3,356
2017-08-18
912
2017-05-31 John Edward Timberlake
See Remarks
See Remarks Buy 4,000 $4.94 $19,760
2017-05-31
30,037
2017-05-22 Erick Lucera
See Remarks
See Remarks Buy 1,500 $4.95 $7,425
2017-05-22
4,500
2017-05-18 Matt Nguyen
See Remarks
See Remarks Buy 1,000 $4.73 $4,730
2017-05-18
6,750
2017-05-17 John Edward Timberlake
See Remarks
See Remarks Buy 5,000 $5.14 $25,700
2017-05-17
26,037
2017-03-28 Royalty L.P.Capital Royalty...
Buy 4,000,000 $10.00 $40,000,000
2017-03-28
1,066,390
2017-03-23 Matt Nguyen
See Remarks
See Remarks Buy 2,500 $10.00 $25,000
2017-03-23
5,750
2017-03-23 Erick Lucera
See Remarks
See Remarks Buy 3,000 $10.00 $30,000
2017-03-23
3,000
2017-03-23 Brian K Roberts
Director
Director Buy 800 $10.00 $8,000
2017-03-23
800
2017-03-23 John Edward Timberlake
See Remarks
See Remarks Buy 10,000 $10.00 $100,000
2017-03-23
21,037
2017-03-23 Geoffrey Jenkins
See Remarks
See Remarks Buy 600 $10.00 $6,000
2017-03-23
6,850

Notable SEC filings of Valeritas Holdings, Inc.

Date Contents
Source
2018-01-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2018-01-08 8-K Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events
2017-12-07 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits
2017-11-08 10-Q Quarterly report
2017-11-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-11-03 8-K Other Events; Financial Statements and Exhibits
2017-10-12 8-K Other Events; Financial Statements and Exhibits
2017-09-22 8-K Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Disclosure; Financial Statements and Exhibits
2017-08-16 8-K Other Events; Financial Statements and Exhibits
2017-08-11 10-Q Quarterly report
2017-08-11 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-06-14 8-K Other Events; Financial Statements and Exhibits
2017-06-09 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events; Financial Statements and Exhibits
2017-05-22 8-K Other Events; Financial Statements and Exhibits
2017-05-12 10-Q Quarterly report
2017-05-12 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-05-05 8-K Other Events; Financial Statements and Exhibits
2017-03-13 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders; Other Events; Financial Statements and Exhibits
2017-02-21 10-K Yearly report
2017-02-21 8-K Entry into a Material Definitive Agreement; Results of Operations and Financial Condition; Unregistered Sales of Equity Securities; Material Modifications to Rights of Security Holders; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Other Events; Financial Statements and Exhibits
2017-02-13 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-02-10 8-K Entry into a Material Definitive Agreement; Other Events; Financial Statements and Exhibits
2016-12-23 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits
2016-12-01 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events; Financial Statements and Exhibits
2016-11-17 8-K Other Events; Financial Statements and Exhibits
2016-11-10 10-Q Quarterly report
Outperform Cowen & Co. 16 April 2017

Valeritas executives

Insider Title Age Since Compensation
John Timberlake (52)
President, Chief Executive Officer, Director since 2016
President, Chief Executive Officer, Director 52 2016 $2,080,420
Geoffrey Jenkins (65)
Executive Vice President - Manufacturing, Operations and Research & Development since 2009
Executive Vice President - Manufacturing, Operations and Research & Development 65 2009 $1,311,820
Matthew Nguyen (47)
Chief Commercial Officer since 2016
Chief Commercial Officer 47 2016 $878,188
Erick Lucera (49)
Chief Financial Officer, Executive Vice President since 2016
Chief Financial Officer, Executive Vice President 49 2016 $484,380
Robert Flamm
Investor Relations since 2017
Investor Relations 2017
Brian Roberts (45)
Independent Director since 2016
Independent Director 45 2016
Joe Mandato (72)
Independent Director since 2016
Independent Director 72 2016
Katherine Crothall (67)
Independent Director since 2016
Independent Director 67 2016
Rodney Altman (54)
Independent Director since 2016
Independent Director 54 2016
Luke Duster (42)
Director since 2016
Director 42 2016
Chris Gregory
Vice President - Research & Development since 2013
Vice President - Research & Development 2013
Scott Huie (52)
Vice President - Regulatory Affairs/Quality Assurance and Compliance since 2016
Vice President - Regulatory Affairs/Quality Assurance and Compliance 52 2016
Hokan Lars Ojert
Vice President - Sales since 2016
Vice President - Sales 2016
Mark Conley (55)
Vice President, Corporate Controller, Treasurer since 2016
Vice President, Corporate Controller, Treasurer 55 2016
Peter Devlin (49)
Chairman of the Board since 2017
Chairman of the Board 49 2017
Valeritas Holdings, Inc. logo

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on developing technologies to treat patients with Type 2 diabetes. It offers V-Go, a disposable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject, a disposable needle-free injection system that delivers drugs ranging from small molecules to large proteins, as well as antibodies and vaccines; and Micro-Trans microneedle array patch technology to deliver drugs into the dermis layer of the skin. In addition, its products include V-Go Prefill, which is in the design-development stage, for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go Link that is in the early stages of development for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors in the United States. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

  • Valeritas Holdings, Inc., 750 Route 202 South, Bridgewater 08807, United States
  • valeritas.com
  • 908-927-9920

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Current assets
Cash $34.085 $42.261 $51.184 $9.866
Short term investments
Net receivables $3.944 $3.39 $4.068 $3.635
Inventory $8.37 $8.118 $8.275 $9.384
Other current assets $1.347 $1.583 $1.026 $1.259
Total current assets $47.746 $55.352 $64.553 $24.144
Long term investments
Property, plant & equipment $9.237 $9.402 $9.789 $10.219
Goodwill
Intangible assets
Other assets $0.25 $0.262 $0.153 $0.153
Deferred long term asset charges
Total assets $57.233 $65.016 $74.495 $34.516
Current liabilities
Accounts payable $11.11 $10.114 $10.199 $10.123
Short long term debt
Other current liabilities $1.191 $1.838 $1.784 $1.623
Total current liabilities $12.301 $11.952 $11.983 $11.746
Long term debt $35.026 $34.122 $33.154 $59.2
Other liabilities $0.007
Deferred long term liabilities $0.03 $0.051 $0.07
Minority interest
Total liabilities $47.334 $46.104 $45.188 $71.016
Stockholders' equity
Stock option warrants
Common stock $0.007 $0.007 $0.007 $0.013
Retained earnings -$458.986 -$448.408 -$436.426 -$424.239
Treasury stock
Capital surplus $468.875 $467.31 $465.723 $387.726
Other stockholder equity
Total stockholder equity $9.899 $18.912 $29.307 -$36.5
Net tangible assets $9.899 $18.912 $29.307 -$36.5
(in millions) 2016 2015 2014
Current assets
Cash $9.866 $2.789 $0.008643
Short term investments
Net receivables $3.635 $3.635
Inventory $9.384 $10.784 $0.000858
Other current assets $1.259 $1.598 $0.01
Total current assets $24.144 $18.806 $0.019501
Long term investments
Property, plant & equipment $10.219 $12.091
Goodwill
Intangible assets
Other assets $0.153 $0.279
Deferred long term asset charges
Total assets $34.516 $31.176 $0.019501
Current liabilities
Accounts payable $10.123 $13.35 $0.050554
Short long term debt $69.133 $0.008222
Other current liabilities $1.623 $1.895
Total current liabilities $11.746 $84.378 $0.058776
Long term debt $59.2
Other liabilities
Deferred long term liabilities $0.07 $0.143
Minority interest
Total liabilities $71.016 $84.521 $0.058776
Stockholders' equity
Stock option warrants
Common stock $0.013 $0.002
Retained earnings -$424.239 -$377.872 -$0.064275
Treasury stock
Capital surplus $387.726 $324.525 $0.025
Other stockholder equity
Total stockholder equity -$36.5 -$53.345 -$0.039275
Net tangible assets -$36.5 -$53.345 -$0.039275

Income statement

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Revenue
Total revenue $5.065 $4.788 $4.611 $4.796
Cost of revenue $3.048 $2.985 $2.878 $3.017
Gross profit $2.017 $1.803 $1.733 $1.779
Operating expenses
Research & development $1.861 $1.65 $1.588 $1.207
Selling, general & administrative $10.02 $11.231 $10.447 $8.934
Non-recurring $0.033
Other operating expenses
Total operating expenses
Operating income -$9.864 -$11.078 -$10.302 -$8.395
Income from continuing operations
Net other income $0.162 -$0.016 $0.08 $0.098
EBIT -$9.702 -$11.094 -$10.222 -$8.297
Interest expense $0.876 $0.888 $1.584 $1.549
Income before tax -$10.578 -$11.982 -$11.806 -$9.846
Income tax expense
Minority interest
Net income from continuing ops -$10.578 -$11.982 -$11.806 -$9.846
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$10.578 -$11.982 -$11.806 -$9.846
Income (for common shares) -$11.135 -$12.531 -$11.854 -$9.846
(in millions) 2016 2015 2014
Revenue
Total revenue $19.55 $18.097 $0.003666
Cost of revenue $12.606 $14.237 $0.001752
Gross profit $6.944 $3.86 $0.001914
Operating expenses
Research & development $4.842 $6.523 $6.523
Selling, general & administrative $33.481 $44.68 $0.06265
Non-recurring $2.394 $2.394 $2.394
Other operating expenses
Total operating expenses
Operating income -$33.773 -$47.343 -$0.060736
Income from continuing operations
Net other income -$0.443 -$3.535 -$3.535
EBIT -$34.216 -$50.878 -$0.060736
Interest expense $12.151 $16.317 $0.003539
Income before tax -$46.367 -$67.195 -$0.064275
Income tax expense
Minority interest
Net income from continuing ops -$46.367 -$67.195 -$0.064275
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$46.367 -$67.195 -$0.064275
Income (for common shares) -$46.367 -$67.195 -$0.064275

Cash flow

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Net income -$10.578 -$11.982 -$11.806 -$9.846
Operating activities
Depreciation $0.476 $0.471 $0.485 $0.835
Net income adjustments $2.358 $2.427 $2.847 $2.037
Change in accounts receivable -$0.554 $0.678 -$0.433 -$0.334
Changes in liabilities $0.351 $0.488 -$0.282 $0.487
Changes in inventory -$0.252 $0.268 $0.998 $0.735
Changes in other operating activities $0.223 -$0.686 $0.213 $0.412
Total cash flow from operations -$7.976 -$8.336 -$7.978 -$5.674
Investing activities
Capital expenditures -$0.239 -$0.084 -$0.043 -$0.002
Investments
Other cash flows from investing $0.033 $0.019 $0.066 $0.013
Total cash flows from investing -$0.206 -$0.065 $0.023 $0.011
Financing activities
Dividends paid
Sale and purchase of stock $0.006 -$0.522 $49.308 $49.308
Net borrowings
Other cash flows from financing
Total cash flows from financing $0.006 -$0.522 $49.273 $49.273
Effect of exchange rate
Change in cash and equivalents -$8.176 -$8.923 $41.318 -$5.663
(in millions) 2016 2015 2014
Net income -$46.367 -$67.195 -$0.064275
Operating activities
Depreciation $6.443 $6.312 $0.003222
Net income adjustments $12.149 $19.724 $19.724
Change in accounts receivable -$0.154 -$0.649 -$0.649
Changes in liabilities -$3.524 $2.081 $0.050554
Changes in inventory $1.4 -$1.196 -$0.000858
Changes in other operating activities $0.392 $0.039 -$0.01
Total cash flow from operations -$29.661 -$40.884 -$0.021357
Investing activities
Capital expenditures -$0.173 -$0.987 -$0.987
Investments
Other cash flows from investing $0.134 $0.134 $0.134
Total cash flows from investing -$0.039 -$0.987 -$0.987
Financing activities
Dividends paid
Sale and purchase of stock $37.158 $23.869 $0.015
Net borrowings -$0.026 -$0.153 $0.015
Other cash flows from financing
Total cash flows from financing $36.777 $23.716 $0.03
Effect of exchange rate
Change in cash and equivalents $7.077 -$18.155 $0.008643
Messenger